Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus
Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Dapagliflozin (Forxiga®) is the first in a novel class of glucose-lowering agents known as sodium-glucose co-transporter-2 (SGLT2) inhibitors and is used in the treatment of patients with type 2 diabetes. By inhibiting the transporter protein SGLT2 in the kidneys, dapagliflozin reduces renal glucose reabsorption, leading to urinary glucose excretio...
Alternative Titles
Full title
Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_crossref_primary_10_2165_11209910_000000000_00000
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_crossref_primary_10_2165_11209910_000000000_00000
Other Identifiers
ISSN
0012-6667
E-ISSN
1179-1950
DOI
10.2165/11209910-000000000-00000
